XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of March 31, 2021.

 

    Carrying     Fair Value Measurement Using  
    Value     Level 1     Level 2     Level 3     Total  
                                         
Derivative warrants liabilities   $     $     $     $     $  

 

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

 

    Carrying     Fair Value Measurement Using  
    Value     Level 1     Level 2     Level 3     Total  
                                         
Derivative warrants liabilities   $ 83,670     $     $     $ 83,670     $ 83,670  
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2021 and the year ended December 31, 2020:

 

   

Fair Value Measurement

Using Level 3

 
    Inputs Total  
Balance, December 31, 2020   $ 83,670  
Change in fair value of derivative warrants liabilities     (83,670 )
Balance, March 31, 2021   $ -  
Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques

The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:

 

    December 31, 2020  
Exercise price     1.25  
Risk free interest rate     0.09 %
Dividend yield     0.00 %
Expected volatility     169 %
Contractual term     0.14 Years  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.

 

    Potentially Outstanding
Dilutive Common Shares
 
    For the Three Months Ended March 31, 2021     For the Three Months Ended March 31, 2020  
             
Conversion Feature Shares                
                 
Common shares issuable under the conversion feature of preferred shares     872,766       872,766  
                 
Stock Options     5,673,861       3,925,682  
                 
Warrants     3,483,767       3,826,658  
                 
Convertible Notes     1,598,000       800,000  
                 
Total potentially outstanding dilutive common shares     11,628,394       9,425,106